Group 1 - The company, Beilu Pharmaceutical, plans to issue shares to no more than 35 specific investors through a simplified procedure for the year 2025 [1] - The issuance price will not be lower than 80% of the average trading price of the company's shares over the 20 trading days prior to the pricing benchmark [1] - The total amount of funds raised from this issuance will not exceed 300 million yuan, and the net proceeds will be fully invested in specific projects including the construction of a production workshop and intelligent warehouse for LZB pharmaceutical [1] Group 2 - The issuance will not exceed 30% of the company's total share capital prior to this issuance [1] - The funds will also be allocated to the technical transformation projects for the production lines of 100 tons of Iodinated Methylpyrrolidone and 50 tons of Iodinated Butanol [1] - Additionally, part of the funds will be used to supplement working capital [1]

格隆汇9月26日｜仙鹤股份：拟定增募资不超过30亿元，用于广西三江口新区高性能纸基新材料项目二 期工程、补充流动资金。 ...

翰宇药业（300199）(300199.SZ)披露2025年度向特定对象发行A股股票预案，公司拟向不超过35名(含 35名)特定投资者发行股票，发行价格不低于定价基准日前20个交易日公司股票交易均价的80%。数量 将按照募集资金总额除以发行价格确定，且不超过公司本次向特定对象发行前总股本的30%(含本数)。 本次发行募集资金总额不超过9.68亿元(含本数)，在扣除相关发行费用后的募集资金净额将全部用于多 肽药物产线及绿色智能化扩建项目、多肽片段扩产建设项目、研发实验室升级项目、司美格鲁肽研发项 目、补充流动资金。 ...

格隆汇9月25日丨翰宇药业(300199.SZ)公布，拟定增募集资金总额不超过人民币96,800.00万元，在扣除 相关发行费用后的募集资金净额将全部用于多肽药物产线及绿色智能化扩建项目、多肽片段扩产建设项 目、研发实验室升级项目、司美格鲁肽研发项目、司美格鲁肽国内上市注射剂（降糖适应症）、司美格 鲁肽美国上市口服片（降糖适应症）、补充流动资金。 ...

人民财讯9月25日电，翰宇药业（300199）9月25日披露2025年度向特定对象发行A股股票预案，拟募资 不超过9.68亿元(含)，用于多肽药物产线及绿色智能化扩建项目、多肽片段扩产建设项目、司美格鲁肽 研发等项目。 ...

Core Viewpoint - The announcement from Amgen Pharmaceuticals indicates that Nanjing Haiqing Pharmaceutical Co., Ltd. plans to subscribe for up to 1.033 billion yuan worth of 164 million ordinary shares, which will make Haiqing the controlling shareholder with a 20% stake, changing the actual controller to individual Zhang Xiantao [1][5]. Group 1: Financial Impact - The total amount raised from the private placement will be used entirely for daily research and operational investments, significantly enhancing the company's cash flow [5][9]. - As of mid-2023, Amgen Pharmaceuticals had cash reserves of 269 million yuan, with negative cash flow from operating activities for several years, and a rising debt-to-asset ratio [1][8]. - The company reported projected revenues of approximately 48 million yuan, 91 million yuan, and 130 million yuan for 2022, 2023, and 2024, respectively, with net losses of 220 million yuan, 421 million yuan, and 441 million yuan during the same period [8]. Group 2: Market Reaction - Following the announcement of the private placement and change in control, Amgen Pharmaceuticals' stock hit the daily limit up on September 23, with a closing price of 9.71 yuan per share, reflecting a 20.02% increase [4][5]. - The trading volume reached 1.01 billion yuan, with a turnover rate of 20.43%, and the total market capitalization reached 6.366 billion yuan [4]. Group 3: Governance Changes - After the completion of the private placement, the board of directors will expand from 7 to 9 members, with Haiqing Pharmaceutical entitled to nominate 5 directors, including a chairman candidate [5][9]. - The introduction of a controlling shareholder is expected to improve the governance structure and provide a more stable leadership and decision-making mechanism for the company's long-term development [9][10]. Group 4: Strategic Considerations - Haiqing Pharmaceutical, established in 1991, focuses on formulation business and has a strong financial capability, which is expected to enhance Amgen's production and research capabilities [5][7]. - Amgen Pharmaceuticals has not yet achieved profitability and relies heavily on external manufacturing, with all products currently outsourced to Huahai Pharmaceutical [6][8]. - The company aims to leverage the new investment to accelerate the commercialization of its products and improve its market position in the field of antibiotic resistance [9][10].

Group 1 - The company Zhongjing Electronics (002579.SZ) announced a plan to issue A-shares to specific investors, aiming to raise no more than 700 million yuan for the construction of a PCB production base in Thailand, technological upgrades in Huizhou, and to supplement working capital [1] - The actual controller of the company, Yang Lin, intends to participate in the subscription with an amount not less than 70 million yuan, accounting for no more than 30% of the total shares issued [1] - The company has reported losses for three consecutive years from 2022 to 2024, with net profits attributable to shareholders of -179 million yuan, -137 million yuan, and -87 million yuan respectively [1] Group 2 - The previous fundraising project, the Zhuhai Fushan high-density printed circuit board construction project (Phase 1), has not met expectations, with cumulative losses of 295 million yuan as of June 30, 2025, compared to a promised benefit of 568 million yuan [1] - The company attributes the losses to changes in the global economic environment leading to a decline in industry prosperity, insufficient capacity utilization, and a prolonged ramp-up period with high fixed costs [1]

盟科药业(688373.SH)披露2025年度向特定对象发行股票预案，公司拟向南京海鲸药业股份有限公司(简 称"海鲸药业")发行1.64亿股，发行价格为6.30元/股。海鲸药业认购金额不超过10.33亿元(含本数)。募集 资金将全部用于公司日常研发与经营投入。发行后，海鲸药业成为公司控股股东，自然人张现涛将成为 公司实际控制人。 ...

智通财经APP讯，盟科药业(688373.SH)披露2025年度向特定对象发行股票预案，公司拟向南京海鲸药 业股份有限公司(简称"海鲸药业")发行1.64亿股，发行价格为6.30元/股。海鲸药业认购金额不超过10.33 亿元(含本数)。募集资金将全部用于公司日常研发与经营投入。发行后，海鲸药业成为公司控股股东， 自然人张现涛将成为公司实际控制人。 ...

Group 1 - The private placement market has seen significant growth this year, with 99 listed companies completing placements, raising a total of 757.34 billion yuan, a year-on-year increase of 534.49% [1] - The industries with the highest number of companies conducting private placements include chemicals, machinery, hardware equipment, electrical equipment, and semiconductors, with 15, 10, 10, 9, and 7 companies respectively [1] - Eight companies raised over 10 billion yuan through private placements, with four major banks raising a combined total of 520 billion yuan [1] Group 2 - A total of 270 listed companies have disclosed private placement plans this year, representing a year-on-year increase of 126.89% [2] - Private placement funding is crucial for the development of companies, particularly in the semiconductor and electrical equipment sectors, enabling them to attract talent and enhance R&D [2] - The active participation of institutional investors in private placements is driven by improved market conditions and positive future expectations [2]